Investor Relations
-
Nov 1, 2019
2nd Quarter Consolidated Financial Results for the Year Ending March 31, 2020
（191.8K）
-
Nov 1, 2019
Presentation for 2nd Quarter Consolidated Financial Results for the Year Ending March 31, 2020
（1,290.1K）
-
May 9, 2019
Notice Concerning Changes of Representative Directors
（127.1K）
-
Aug 6, 2018
Notice regarding 100% share acquisition of LOMA Holding GmbH, a German pharmaceutical contract development and manufacturing organization
-
Aug 2, 2018
1st Quarter Consolidated Financial Results for the Year Ending March 31, 2019
（128.1K）
* THE INCLUSION OF DAICEL CORPORATION IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAICELCORPORATION BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.